A recent study conducted by UCLA Health Jonsson Comprehensive Cancer Center researchers found that new, non-invasive imaging ...
A new study led by investigators from the UCLA Health Jonsson Comprehensive Cancer Center has demonstrated a new, ...
A recent study conducted by UCLA Health Jonsson Comprehensive Cancer Center researchers found that new, non-invasive imaging ...
Renal cell carcinoma (RCC) represents a group of diseases linked by their primary site of origin, the kidney. Studies of families with a genetic predisposition to the development of kidney cancer ...
UCLA Health researchers unveiled a novel non-invasive imaging technique that accurately detects clear-cell renal cell ...
Fotivda monotherapy may show better outcomes in second-line therapy than the combination of Opdivo and Fotivda in metastatic ...
Genenta Science (NASDAQ: GNTA), a pioneer in immuno-oncology and a leader in cell-based therapeutics, is pleased to announce that the Agenzia Italiana del Farmaco (AIFA) has approved a new Phase 1 ...
No benefit seen for rechallenge with nivolumab after progression in the post-immune checkpoint inhibitor setting.
The following is a summary of “Frailty and Renal Cell Carcinoma: Integration of Comprehensive Geriatric Assessment into ...
The healthcare brand offers paid research opportunities for patients and family caregivers in the USNew Hope, Pennsylvania--(Newsfile Corp. - ...
Toni Choueiri, MD, discusses the rationale behind the drug combination of tivozanib and nivolumab in the TiNivo-2 study.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback